These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24917219)

  • 1. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
    Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
    Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
    Kurozumi S; Padilla M; Kurosumi M; Matsumoto H; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Ranger-Moore J; Allred DC; Dennis E; Nitta H
    Breast Cancer Res Treat; 2016 Jul; 158(1):99-111. PubMed ID: 27318853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
    Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
    Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
    Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
    Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
    Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.
    Hou Y; Nitta H; Li Z
    Am J Clin Pathol; 2017 Jan; 147(1):89-95. PubMed ID: 28110280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of HER2 gene amplification and tumor progression in early gastric cancer.
    Kanayama K; Imai H; Usugi E; Shiraishi T; Hirokawa YS; Watanabe M
    Virchows Arch; 2018 Nov; 473(5):559-565. PubMed ID: 30120594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
    Catenacci DVT; Liao WL; Zhao L; Whitcomb E; Henderson L; O'Day E; Xu P; Thyparambil S; Krizman D; Bengali K; Uzzell J; Darfler M; Cecchi F; Blackler A; Bang YJ; Hart J; Xiao SY; Lee SM; Burrows J; Hembrough T
    Gastric Cancer; 2016 Oct; 19(4):1066-1079. PubMed ID: 26581548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
    Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
    Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
    Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
    Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The assessment of HER2 status in breast cancer: the past, the present, and the future.
    Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
    Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.